Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells

International Journal of Cancer

Volumn 83, Issue 4, 1999, Pages 571-576

  Post, Jacob ^a,c   Vooijs, Wim C ^a   Bast, Bert J E G ^b   De Gast, Gijsbert C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IMMUNOTOXIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; DRUG EFFICACY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; MYELOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTOXINS; LEUCINE; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; P-GLYCOPROTEIN; PROTEIN BIOSYNTHESIS; PROTEOGLYCANS; SYNDECAN-1; SYNDECANS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VERAPAMIL;

EID: 0032859718     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991112)83:4<571::AID-IJC21>3.0.CO;2-N     Document Type: Article

References (33)

1. BAST, R.C., DE FABRITHS, P., LIPTON, J., GELBER, R., MAVER, C., NADLER, L., SALLAN, S. and RITZ, J., Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res., 45, 499-504 (1985).
2. CHABNER, B.A. and WILSON, W., Reversal of multidrug resistance. J. clin. Oncol., 9, 4-6 (1991).
3. CHIGNOLA, R., PASTI, M., CANDIANI, C., FRANCESCHI, A., ANSELMI, C., TRIDENTE, G. and COLOMBATTI, M., Escape mechanisms of human leukemic cells to long-term immunotoxin treatment in an in vitro experimental model. Int. J. Cancer, 61, 535-541 (1995).
4. CLEMENT, C., VOOYS, W.C., KLEIN, B. and WIJDENESS, J., B-B2 and B-B4, two new Moabs against secreting plasma cells. In: S. Schlossman, (eds.), Proceedings of the Vth international workshop and conference on human leukocyte differentiation antigens, p. 714, Oxford University Press, Oxford (1995).
5. COLE, S.P.C., BHARDWAJ, G., GERLACH, J.H., MACKIE, C.E., GRANT, C.E., ALMQUIST, K.C., STEWART, A.J., KURZ, E.U., DUNCAN, A.M.V. and DEELY, R.G., Over-expression of a transporter gene in a multidrug-resistant human lung-cancer cell line. Science, 258, 1650-1654 (1992).
6. DALTON, W.S., DURIE, B.G., ALBERTS, D.S., GERLACH, J.H. and CRESS, A.E., Characterisation of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res., 46, 5125-5130 (1986).
7. DALTON, W.S. and SALMON, S.E., Drug resistance in myeloma: mechanisms and approaches to circumvention. Hematol. Oncol. Clin. N. Amer., 6, 383-393 (1992).
8. EK, O., GAYNON, P., ZEREN, T., CHELSTROM, L.M., MYERS, D.E. and UCKUN, R.M., Treatment of human B-cell-precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone and L-asparaginase. Leuk. Lymphoma, 31, 143-149 (1998).
9. FERRAND, V.L., MONTERO JULIAN, F.A., CHAUVET, M.M., HIRN, M.H. and BOURDEAUX, M.J., Quantitative determination of the MDR-related P-glycoprotein, P-gp 170, by a rapid flow-cytometric technique. Cytometry, 23, 120-125 (1996).
10. FISHER, G.A. and SIKIC, B.I., Clinical studies with modulators of multidrug resistance. Hematol Oncol. Clin. N. Amer., 9, 363-382 (1995).
11. GERLACH, J.H., ENDICOTT, J.A., JURANKA, P.J., HENDERSON, G., SARANGI, F., DEUCHARS, K.L. and LING, V., Homology between P-glycoprotein and a bacterial haemolysin transport protein suggest a model for multidrug resistance. Nature (Lond.), 324, 485-489 (1986).
12. GHETIE, M-A., PODAR, E.M., GORDON, B.E., PANTAZIS, P., UHR, J.W. and VITETTA, E.S., Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer, 68, 93-96 (1996).
13. GHETIE, V. and VITETTA, E.S., Immunotoxins in the therapy of cancer: from bench to clinic. Pharmacol. Ther., 63, 209-234 (1994).
14. GIESLER, F. and NUBLER, V., Cellular-resistance mechanisms with impact on the therapy of multiple myeloma. Leukemia, 12, 1009-1012 (1998).
15. HAJEK, R., ADAM, Z., KIRVANOVA, A., DOUBEK, M., KORISTEK, Z. and VORLICEK, J., Current role of immunotherapy in multiple myeloma. Acta med. Austriaca, 25, 79-85 (1998).
16. HAMADA, H. and TSURUO, T., Functional role for the 170-180-kDa glycoprotein specific to drug-resistant tumour cells revealed by monoclonal antibodies. Proc. nat. Acad. Sci. (Wash.), 83, 7785-7789 (1986).
17. HARADA, H., KAWANO, M.M., HUANG, N., HARADA, Y., IWATO, K., TANABE, O., TANAKA, H., SAKI, A. and KURAMOTO, A., Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 81, 2658-2663 (1993).
18. HUANG, Y.W. and VITETTA, E.S., Immunotherapy of multiple myeloma. Stem Cells, 13, 123-134 (1995).
19. JAFFREZOU, J-P. and LAURENT, G., The intriguing link between modulation of both multidrug resistance and ligand-toxin conjugate cytotoxicity. FEBS Lett., 323, 191-197 (1993).
20. LIDOR, Y.J., O'BRIANT, K.C., XU, F.J., HAMILTON, T.C., OZOLS, R.F. and BAST, R.C., Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian-cancer cells. J. clin. Invest., 92, 2440-2447 (1993).
21. LIU, C., LAMBERT, J.M., TEICHER, B.A., BLATTLER, W.A. and O'CONNOR, R., Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs. Blood, 87, 3892-3898 (1996).
22. MARIE, J.-P., P-glycoprotein in adult hematologic malignancies. Hematol. Oncol. Clin. N. Amer., 9, 239-249 (1995).
23. MOOLTEN, F. and COOPERBAND, S.R., Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cell. Science, 169, 68-70 (1970).
24. MOSCOW, J.A. and COWAN, K.H., Multidrug resistance. J. nat. Cancer Inst., 80, 14-20 (1988).
25. NOSSAL, G.J.V., Minimal residual disease as the target for immunotherapy of cancer. Lancet, 343, 1172-1174 (1994).
26. O'CONNOR, R., LIU, C., FERRIS, C.A., GUILD, B.C., TEICHER, B.A., CORVI, C., LIU, Y., ARCECI, R.J., GOLDMACHER, V.S., LAMBERT, J.M. and BLATTLER, W.A., Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumours. Blood, 86, 4286-4294 (1995).
27. POST, J., VOOYS, W.C., DE GAST, G.C. and BAST, B.E.J., Comparison of various in vitro assays for efficacy screening of immunotoxins. Leukemia Res., 19, 241-247 (1995).
28. ROSENBLUM, M.G., CHEUNG, L., KIM, S.K.K., MUJOO, K., DONATO, N.J. and MURRAY, J.L., Cellular resistance to the anti-melanoma immunotoxin ZME-gelonin and strategies to target-resistant cells. Cancer Immunol. Immunother., 42, 115-121 (1995).
29. SCADDEN, D.T., SCHENKEIN, D.P., BERNSTEIN, Z., LUSKEY, B., DOWEIKO, J., TULPULE, A. and LEVINE, A.M., Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer, 83, 2580-2587 (1998).
30. r-110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res., 53, 1475-1479 (1993).
31. THRUSH, G.R., LARK, L.R., CLINCHY, B.C. and VITETTA, E.S., Immunotoxins: an update. Ann. Rev. Immunol., 14, 49-71 (1996).
32. VOOYS, W.C., POST, J., WIJDENESS, J., SCHUURMAN, H.-J., BOLOGNESI, A., POLITO, L., STIRPE, F., BAST, E.J.E.G. and DE GAST, G.C., Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol. Immunother., 42, 319-328 (1996).
33. YOKOTA, S., HARA, H., LUO, Y. and SEON, B.K., Synergistic potentation of in vivo anti-tumor activity of anti-human T-leukemia immunotoxins by recombinant α-interferon and daunorubicin. Cancer Res., 50, 32-37 (1990).